NCT00437281 - Safety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Epilepsies, Partial

Interventions

DRUG

Placebo

DRUG

Pregabalin

Orally-administered pregabalin

Trial Locations (18)

14222

Pfizer Investigational Site, Buffalo

27710

Pfizer Investigational Site, Durham

32504

Pfizer Investigational Site, Pensacola

32561

Pfizer Investigational Site, Gulf Breeze

33603

Pfizer Investigational Site, Tampa

33609

Pfizer Investigational Site, Tampa

36604

Pfizer Investigational Site, Mobile

36693

Pfizer Investigational Site, Mobile

44280

Pfizer Investigational Site, Guadalajara

65804

Pfizer Investigational Site, Springfield

72205

Pfizer Investigational Site, Little Rock

72401

Pfizer Investigational Site, Jonesboro

77030

Pfizer Investigational Site, Houston

78258

Pfizer Investigational Site, San Antonio

85016

Pfizer Investigational Site, Phoenix

94143

Pfizer Investigational Site, San Francisco

06720

Pfizer Investigational Site, Mexico City

120-752

Pfizer Investigational Site, Seoul

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY